Business
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE
About this update from Pulmonx Corporation
[{"type":"text","content":"CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits to patients treated with Zephyr® Valves REDWOOD CITY, Calif. & VIENNA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced the presentation of clinical data from the AeriSeal® CONVERT trial and 5-year follow-up data from the LIBERATE study at the European Respiratory Society (ERS) Congress in Vienna, Austria. Presented data from the CONVERT trial demonstrated that treatment with the AeriSeal System is safe and effective in occluding small airways and/or collateral air channels allowing patients with collateral ventilation to undergo and benefit from treatment with Zephyr® Endobronchial Valves. Presented 5-year follow-up data from the LIBERATE study showed patients treated with Zephyr Valves experience durable improvements in lung function out to at least 5 years. AeriSeal CONVERT Trial Professor Kaid Darwiche, Head, Department of Interventional Pneumology, Ruhrlandklinik, Essen, Germany gave a presentation titled, Zephyr Valve benefits previously ineligible patients after blocking of collateral channels with AeriSeal: CONVERT Trial. The reported data from the full 101-patient cohort in the CONVERT trial demonstrated 77.6% of patients with collateral ventilation (CV+) treated with AeriSeal successfully experienced conversion. Furthermore, following conversion, patients treated with Zephyr Valves experienced clinically meaningful improvements over the baseline with: Improved lung function of 80mL or 10.2% over the baseline as measured by Forced Expiratory Volume in 1 second (FEV1)Improvement of 6.3 points in quality of life measured by the St. George’s Respiratory QuestionnaireMean treated lobe volume reduction (TLVR) of greater than one liter at 45 days89% of CV- converted patients achieved a TLVR equal to or greater than 350mL, the minimal clinical important difference, at 6-months following valve implantation These findings show that patients with collateral ventilation can successfully undergo bronchoscopic lung volume reduction (BLVR) with Zephyr Valves following closure of the fissure gap with the AeriSeal System. ...